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Vaccines and IP Preparedness in the
Coronavirus Outbreak
May 18, 2020 Ana Santos Rutschman
The COVID-19 pandemic has shed renewed light on the importance of
research and development (R&D) on biopharmaceutical products needed to
prevent or lessen the burden posed by outbreaks of infectious diseases.
Among these, the need for new vaccines has become of paramount
importance. While a race to develop different types of vaccines unfolds at
unusual speed, there are still significant shortcomings in the ecosystem that
leads to the production and dissemination of vaccines targeting infectious
diseases like COVID-19.
In the wake of the Ebola and Zika outbreaks, I wrote about the need for
Intellectual Property (IP) preparedness. The concept borrows from the World
Health Organizationʼs finding of a lack of R&D preparedness in the infectious
disease domain, combining it with the framework for emergency preparedness
and response in the field of public health law. Lack of R&D preparedness
results in part from chronic underinvestment in products targeting diseases
traditionally overlooked by the larger players in biopharma. Emerging
coronavirus R&D has long been on the WHO list of underfunded R&D
pipelines. This is at odds with notions of public health preparedness, which
prescribe a supple set of mechanisms to prevent or respond to an outbreak,
including the production and deployment of vaccines as soon as needed
and/or possible.
These problems have two important IP angles to them. First, because IP is still
regarded as the default legal regime to incentivize innovation (even if clearly it
is not the only one, and often not even the most appropriate), certain socially
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valuable goods, including many types of vaccines, fail to attract desirable
levels of R&D—absent a public health crisis of atrocious proportions, as
exemplified by COVID-19. Second, even when a public health crisis serves as
a catalyst for R&D, rules and practices affecting the licensure and
commercialization of vaccines may still prevent indicated populations (or at
least the poorer segments thereof) from accessing vaccines: in February,
Secretary of Health and Human Services Alex Azar suggested that there can
be no price controls on coronavirus vaccines because they would have chilling
effects on private sector investment down the road.
Both the incentives and the pricing issues arising in the vaccine IP space
during COVID-19 magnify old problems, last observed in connection with
Ebola and Zika vaccine R&D. Current IP systems—which grant exclusivity
regimes as a carrot for innovation—function poorly as incentives mechanisms
before an outbreak occurs. Companies moved primarily by the prospective
function of patents tend to concentrate R&D resources on large, permanent
markets with repeat consumers—features that most vaccine markets normally
lack. And when an outbreak temporarily fixes ongoing incentives problems, IP
rights can still be brandished in ways that overextend market exclusivity to the
detriment of vaccine affordability.
How can IP preparedness for vaccines increase ahead of the next major public
health crisis? A few interesting things are happening that could provide an
answer to this question. At the incentives level, the National Institutes of
Health announced the formation of a public-private partnership to bolster
COVID-19 R&D, including vaccine development. The first of these large-scale
public-private partnerships fully dedicated to vaccine R&D on emerging
infectious disease pathogens, CEPI, was created after the 2014–2016 Ebola
outbreak. With regard to the licensure of IP needed for COVID-19 R&D, an
unprecedented pledge was recently launched. Participating entities committed
to share their IP non-exclusively and free of charge until one year after the end
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of the pandemic. And, finally, from the commercialization perspective, there
has been some pressure for COVID-19 vaccines resulting from ongoing R&D
to be priced affordably, although the practical effects of such pressure remain
to be seen.
All of this is a start. Moving forward, however, we need to get past temporary
fixes and reexamine the enduring, systemic holes in IP theory and practice that
got us here in the first place.
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